眼科疾患治療の市場規模、シェア、成長分析、疾患適応症別、薬剤クラス別、地域別 - 産業予測、2025～2032年

眼科疾患治療2023年の市場規模は335億米ドルで、2024年の355億4,000万米ドルから2032年には570億8,000万米ドルに成長し、予測期間中（2025-2032年）のCAGRは6.10%で推移する見通しです。

眼科治療の世界市場は、眼疾患の罹患率の上昇と視力ケアに対する需要の高まりに牽引され、大きな成長を遂げようとしています。米国国立眼科研究所（National Eye Institute）は、視力に関連する疾病が米国経済に年間約1,390億米ドルの損失をもたらしていることを明らかにしています。大手製薬会社は網膜障害の革新的治療に多額の投資を行っており、近い将来にはより高度な治療法が承認される見込みです。さらに、アジア市場では費用対効果の高い市販眼科薬の登場が世界の収益を押し上げる可能性が高いです。抗炎症薬、抗感染薬、抗VEGF薬、抗緑内障治療薬が市場を独占しており、抗炎症薬は2019年に27％のシェアを獲得し、予測期間中も主導的地位を維持すると予想されます。

目次

イントロダクション

• 調査の目的
• 調査範囲
• 定義

調査手法

• 情報調達
• 二次データと一次データの方法
• 市場規模予測
• 市場の前提条件と制限

エグゼクティブサマリー

• 世界市場の見通し
• 供給と需要の動向分析
• セグメント別機会分析

市場力学と見通し

• 市場概要
• 市場規模
• 市場力学
  • 促進要因と機会
  • 抑制要因と課題
• ポーターの分析

主な市場の考察

• 重要成功要因
• 競合の程度
• 主な投資機会
• 市場エコシステム
• 市場の魅力指数（2024年）
• PESTEL分析
• マクロ経済指標
• バリューチェーン分析
• 価格分析

眼科疾患治療市場規模：薬剤クラス別

• 市場概要
• 抗炎症
• 抗感染薬
• 抗VEGF
• 緑内障予防
  • ベータ遮断薬
  • プロスタグランジン類似体
  • アルファアドレナリン作動薬
  • 炭酸脱水酵素阻害剤
  • 併用薬
  • その他
• その他

眼科疾患治療市場規模：剤形別

• 市場概要
• 固体
• 液体
• 半固体

眼科疾患治療市場規模：疾患適応症別

• 市場概要
• 緑内障
  • 開放隅角緑内障
  • 閉塞隅角緑内障
  • その他
• ドライアイ
• 網膜疾患
• 糖尿病黄斑浮腫（DME）
• 黄斑変性症（AMD）
• 糖尿病網膜症（DR）
• 網膜静脈閉塞症（RVO）
• アレルギーと感染症
• その他

眼科疾患治療市場規模：流通チャネル別

• 市場概要
• 病院薬局
• 小売薬局とオンライン薬局

眼科疾患治療市場規模

• 北米
  • 米国
  • カナダ
• 欧州
  • ドイツ
  • スペイン
  • フランス
  • 英国
  • イタリア
  • その他欧州地域
• アジア太平洋地域
  • 中国
  • インド
  • 日本
  • 韓国
  • その他アジア太平洋地域
• ラテンアメリカ
  • ブラジル
  • その他ラテンアメリカ地域
• 中東・アフリカ
  • GCC諸国
  • 南アフリカ
  • その他中東・アフリカ

競合情報

• 上位5社の比較
• 主要企業の市場ポジショニング（2024年）
• 主な市場企業が採用した戦略
• 市場の最近の動向
• 企業の市場シェア分析（2024年）
• 主要企業の企業プロファイル
  • 会社概要
  • 製品ポートフォリオ分析
  • セグメント別シェア分析
  • 収益の前年比比較（2022-2024）

主要企業プロファイル

• Novartis AG（Switzerland）
• Roche Holding AG（Switzerland）
• Regeneron Pharmaceuticals, Inc.（USA）
• Allergan（part of AbbVie）（USA）
• Bausch Health Companies Inc.（Canada）
• Pfizer Inc.（USA）
• Merck & Co., Inc.（USA）
• Santen Pharmaceutical Co., Ltd.（Japan）
• Teva Pharmaceutical Industries Ltd.（Israel）
• Otsuka Pharmaceutical Co., Ltd.（Japan）
• Alcon Inc.（Switzerland）
• Aerie Pharmaceuticals, Inc.（USA）
• Omeros Corporation（USA）
• Kodiak Sciences Inc.（USA）
• EyePoint Pharmaceuticals, Inc.（USA）
• Johnson & Johnson（USA）
• Abbott Laboratories（USA）
• Carl Zeiss Meditec AG（Germany）
• Topcon Corporation（Japan）
• Hoya Corporation（Japan）

結論と推奨事項

Ophthalmic Disease Therapeutics Market size was valued at USD 33.5 Billion in 2023 and is poised to grow from USD 35.54 Billion in 2024 to USD 57.08 Billion by 2032, growing at a CAGR of 6.10% during the forecast period (2025-2032).

The global market for ophthalmic therapeutics is set for significant growth, driven by the rising incidence of ocular diseases and an escalating demand for vision care. The National Eye Institute highlights that vision-related ailments cost the U.S. economy approximately $139 billion annually. Major pharmaceutical firms are heavily investing in innovative therapies for retinal disorders, with more advanced treatments expected to gain approval in the near future. Additionally, the advent of cost-effective over-the-counter ophthalmic drugs in Asian markets is likely to boost global revenues. Anti-inflammatory, anti-infectives, anti-VEGF, and anti-glaucoma treatments dominate the market, with anti-inflammatory drugs capturing a substantial 27% share in 2019 and expected to maintain a leading position throughout the forecast period.

Top-down and bottom-up approaches were used to estimate and validate the size of the Ophthalmic Disease Therapeutics market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Ophthalmic Disease Therapeutics Market Segmental Analysis

Global Ophthalmic Disease Therapeutics Market is segmented by Drug Class, Dosage Form, Disease Indication, Distribution Channel and region. Based on Drug Class, the market is segmented into anti-inflammatory, anti-infectives, Anti-VEGF, anti-glaucoma and others. Based on Dosage Form, the market is segmented into solid, liquid and semisolid. Based on Disease Indication, the market is segmented into glaucoma, dry eye disease, retinal diseases, allergy & infections and others. Based on Distribution Channel, the market is segmented into hospital pharmacies and retail & online pharmacies. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Ophthalmic Disease Therapeutics Market

The growth of the ophthalmic disease therapeutics market is significantly driven by the increasing presence of small and mid-sized companies that are diversifying the competitive landscape. Key industry players, including Allergan plc, F. Hoffmann-La Roche AG, and Regeneron Pharmaceuticals, Inc., compete alongside these smaller entities, leading to a fragmented market. This competition fosters innovation and the development of new treatment options for prevalent ophthalmic conditions such as macular degeneration, macular edema, and retinal vein occlusion. Established treatments like Eylea from Regeneron and Lucentis from F. Hoffmann-La Roche continue to play pivotal roles in effectively managing these diseases, further stimulating market expansion.

Restraints in the Ophthalmic Disease Therapeutics Market

The Ophthalmic Disease Therapeutics market faces significant constraints primarily due to the extended timelines required for the manufacturing and formulation of ophthalmic medications. Additionally, the potential side effects associated with these drugs pose another challenge that could hinder market expansion during the forecast period. The complexity of developing these treatments, coupled with the need for thorough testing and regulatory approvals, often results in delays that may deter investment and innovation in this sector. Consequently, these factors are anticipated to limit the overall growth potential of the ophthalmic therapeutics market in the foreseeable future.

Market Trends of the Ophthalmic Disease Therapeutics Market

The Ophthalmic Disease Therapeutics market is witnessing a robust trend driven by rapid technological advancements in ophthalmology, particularly in imaging techniques and surgical tools that enhance patient outcomes. Innovations such as femtosecond lasers in cataract surgery exemplify the shift towards more precise and safer procedures, minimizing complications and improving recovery times. Additionally, the integration of artificial intelligence in diagnostic tools is streamlining patient assessments, allowing for earlier detection and personalized treatment approaches. As a result, these developments are attracting investment and market interest, thereby fostering growth and significantly enhancing the overall landscape of ophthalmic disease management.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis

Global Ophthalmic Disease Therapeutics Market Size by Drug Class & CAGR (2025-2032)

• Market Overview
• Anti-Inflammatory
• Anti-Infectives
• Anti-VEGF
• Anti-Glaucoma
  • Beta Blockers
  • Prostaglandins Analogs
  • Alpha Adrenergic Agonists
  • Carbonic Anhydrase Inhibitors
  • Combination Drugs
  • Others
• Others

Global Ophthalmic Disease Therapeutics Market Size by Dosage Form & CAGR (2025-2032)

• Market Overview
• Solid
• Liquid
• Semisolid

Global Ophthalmic Disease Therapeutics Market Size by Disease Indication & CAGR (2025-2032)

• Market Overview
• Glaucoma
  • Open Angle Glaucoma
  • Angle Closure Glaucoma
  • Others
• Dry Eye Disease
• Retinal Diseases
• Diabetic Macular Edema (DME)
• Macular Degeneration (AMD)
• Diabetic Retinopathy (DR)
• Retinal Vein Occlusion (RVO)
• Allergy & Infections
• Others

Global Ophthalmic Disease Therapeutics Market Size by Distribution Channel & CAGR (2025-2032)

• Market Overview
• Hospital Pharmacies
• Retail & Online Pharmacies

Global Ophthalmic Disease Therapeutics Market Size & CAGR (2025-2032)

• North America (Drug Class, Dosage Form, Disease Indication, Distribution Channel)
  • US
  • Canada
• Europe (Drug Class, Dosage Form, Disease Indication, Distribution Channel)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Drug Class, Dosage Form, Disease Indication, Distribution Channel)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Drug Class, Dosage Form, Disease Indication, Distribution Channel)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Drug Class, Dosage Form, Disease Indication, Distribution Channel)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• Novartis AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Roche Holding AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Regeneron Pharmaceuticals, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Allergan (part of AbbVie) (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bausch Health Companies Inc. (Canada)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co., Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Santen Pharmaceutical Co., Ltd. (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Teva Pharmaceutical Industries Ltd. (Israel)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Otsuka Pharmaceutical Co., Ltd. (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Alcon Inc. (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Aerie Pharmaceuticals, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Omeros Corporation (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Kodiak Sciences Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• EyePoint Pharmaceuticals, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Abbott Laboratories (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Carl Zeiss Meditec AG (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Topcon Corporation (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Hoya Corporation (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations